These statistics provide a strong foundation for setting realistic expectations and demonstrate that tirzepatide is a powerful tool for chronic weight management Results vary based on dose, lifestyle, and individual response
Tirzepatide, a dual GIP/GLP-1 receptor agonist approved by the FDA for diabetes management and chronic weight management, works by enhancing insulin secretion, suppressing glucagon, and reducing appetite
The bottom line The emergence of medications like tirzepatide represents an exciting development in sleep apnea treatment
Common side effects during the first two weeks include mild nausea, decreased appetite, and occasional GI discomfort
Combining tirzepatide treatment with a balanced diet, physical activity, and regular professional follow-ups maximizes results